OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On November8, 2017, OPKO Health, Inc., a Delaware corporation (the “Company”), issued a press release announcing operating and financial highlights for the quarter ended September30, 2017. A copy of the press release is attached hereto as Exhibit 99.1.
The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02. | Regulation FD Disclosure. |
On November3, 2017, the Company issued a press release announcing that it will hold a conference call to provide a business update and discuss its third quarter financial and operating results. A copy of the press release is attached hereto as Exhibit 99.2.
The information included herein and in Exhibit 99.2 shall not be deemed “filed” for purposes of Section18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02. | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
| 99.1 | Press Release of the Company dated November8, 2017 |
| 99.2 | Press Release of the Company dated November3, 2017 |
Exhibit List
Opko Health, Inc. ExhibitEX-99.1 2 d490503dex991.htm EX-99.1 EX-99.1 EXHIBIT 99.1 OPKO Health Reports 2017 Third Quarter Highlights and Financial Results • RAYALDEE total prescriptions increased 66% in Q3 2017 compared with Q2 2017 • 4Kscore utilization increased 19% in Q3 2017 compared with Q3 2016 • 4Kscore TV ads in the Northeast to begin November 21 • Submitted a Premarket Approval (PMA) application with FDA for Claros point-of-care (POC) prostate specific antigen (PSA) test • Exclusive agreement with Japan Tobacco to develop and commercialize RAYALDEE in Japan • Enrollment for global pediatric Phase 3 hGH-CTP clinical trial continues; Japanese pediatric registration trial underway • Intravenous VARUBI® approved by US FDA with launch expected November 2017; addresses 90% of the market for chemotherapy induced nausea and vomiting (CINV); OPKO to receive double digit royalties • Plans to initiate four Phase 2 programs in late 2017 or early 2018 • Consolidated revenue for the three months ending September 30,…To view the full exhibit click here
About OPKO Health, Inc. (NASDAQ:OPK)
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.
